BackElevance Health Overview
Elevance Health Inc

Elevance Health Target Price

Analysts' average 12-month price target for Elevance Health is $440.

Get informed when a big investor buys or sells

+ Follow

Share Price

$390.24

Average Target Price

$437.8812.2% upside

26 analysts in the last 4 months

High: $498 | Low: $331

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-17Leerink Partners$3951.2% upsideOpen
2026-07-16Bernstein$48825.1% upsideOpen
2026-07-16Barclays$45717.1% upsideOpen
2026-07-16Wells FargoStephen Baxter$47321.2% upsideOpen
2026-07-16Guggenheim$45516.6% upsideOpen
2026-07-16Robert W. Baird$3930.7% upsideOpen
2026-07-16Goldman Sachs$3951.2% upsideOpen
2026-07-16RBC Capital$4248.7% upsideOpen
2026-07-16New Street$48223.5% upsideOpen
2026-07-14Truist Financial$47521.7% upsideOpen
2026-07-13Wells Fargo$49226.1% upsideOpen
2026-07-09RBC CapitalBen Hendrix$43912.5% upsideOpen
2026-07-07Raymond JamesSarah James$45015.3% upsideOpen
2026-07-02Bernstein$48223.5% upsideOpen
2026-06-08Mizuho Securities$46519.2% upsideOpen
2026-06-04Morgan Stanley$4043.5% upsideOpen
2026-06-01Truist FinancialDavid MacDonald$45015.3% upsideOpen
2026-05-26BarclaysAndrew Mok$48023% upsideOpen
2026-05-22UBS$46017.9% upsideOpen
2026-05-20Deutsche Bank$49827.6% upsideOpen
2026-05-20Mizuho Securities$43511.5% upsideOpen
2026-04-24Barclays$4084.6% upsideOpen
2026-04-24Guggenheim$3992.2% upsideOpen
2026-04-23Leerink Partners$3646.7% downsideOpen
2026-04-23Robert W. Baird$33115.2% downsideOpen
2026-04-20JefferiesDavid Windley$3910.2% upsideOpen
2026-03-10Mizuho SecuritiesAnn Hynes$35010.3% downsideOpen
2026-02-03RBC Capital$3588.3% downsideOpen
2026-02-02Truist Financial$3900.1% downsideOpen
2026-02-02Piper Sandler$4094.8% upsideOpen
2026-02-02Craig-Hallum$4094.8% upsideOpen
2026-02-01Bernstein$4094.8% upsideOpen
2026-01-30Wells Fargo$3910.2% upsideOpen
2026-01-30Barclays$3930.7% upsideOpen
2026-01-29UBS$4002.5% upsideOpen
2026-01-29Deutsche Bank$33214.9% downsideOpen
2026-01-29GuggenheimJason Cassorla$3961.5% upsideOpen
2026-01-22GuggenheimJason Cassorla$4146.1% upsideOpen
2026-01-09Mizuho SecuritiesAnn Hynes$4135.8% upsideOpen
2026-01-08Wolfe ResearchJustin Lake$4258.9% upsideOpen
2026-01-07Wells Fargo$4248.7% upsideOpen
2026-01-06Bernstein$43110.4% upsideOpen
2026-01-05BarclaysAndrew Mok$4043.5% upsideOpen
2025-12-19Deutsche BankGeorge Hill$32018% downsideOpen
2025-12-18Morgan Stanley$3529.8% downsideOpen
2025-11-03Mizuho Securities$4002.5% upsideOpen
2025-10-22Barclays$3851.3% downsideOpen
2025-10-21Bernstein$4207.6% upsideOpen
2025-10-14Goldman Sachs$34312.1% downsideOpen
2025-10-14Truist Financial$4002.5% upsideOpen

Elevance Health (ELV) FAQ

Elevance Health's target price stands at $440. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $440 for ELV implies 12.2% upside versus today's price ($390.24). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Elevance Health's target price evolved across reporting periods, while the comparison chart places ELV next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Finance, target price is commonly used to spot outliers. Elevance Health's reading of $440 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.